Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
oshadi d + oshadi r
- Development stage
- Unknown
- Lead developer
- Oshadi Drug Administration
- Modality
- Therapeutic Enzymes → Recombinant Proteins and Enzymes, Small Molecules
- Administration
- Oral
01
Overview
Oshadi D + Oshadi R is a combination of two investigational anti-cancer agents developed by Oshadi Drug Administration Ltd. Oshadi D consists of DNase (deoxyribonuclease) formulated in a proprietary carrier, while Oshadi R consists of RNase (ribonuclease) in the same carrier. The combination is designed to degrade extracellular DNA and RNA within the tumor microenvironment, thereby disrupting cancer cell survival mechanisms and potentially enhancing the efficacy of chemotherapy. Preclinical and early clinical studies have shown that this combination has anti-tumor activity with a favorable safety profile when used alongside standard chemotherapies such as docetaxel or salvage regimens. The drugs are administered orally and have been evaluated for use in relapsed or refractory acute myeloid leukemia (AML), acute lymphoblastic leukemia (ALL), metastatic non-small cell lung cancer (NSCLC), malignant mesothelioma, and basal cell carcinoma[2][3][4].
- Other names
- DNase in Oshadi carrier + RNase in Oshadi carrier
02
Targets
Ribonuclease A familyDNASE1 (Deoxyribonuclease I)
Beyond the preview
Go deeper on oshadi d + oshadi r.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on oshadi d + oshadi r.